Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34407545

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2021 Dec 30
First author
Wang XV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2021 Dec 30;138(26):2746-2747. doi: 10.1182/blood.2021013435.
    note
    Source null
    related pmid
    34967869
    relationship
    Comment in

Authors and identifiers

  1. name
    Wang XV
    type
    Author
  2. name
    Hanson CA
    type
    Author
  3. name
    Tschumper RC
    type
    Author
  4. name
    Lesnick CE
    type
    Author
  5. name
    Braggio E
    type
    Author
  6. name
    Paietta EM
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Barrientos JC
    type
    Author
  9. name
    Leis JF
    type
    Author
  10. name
    Zhang CC
    type
    Author
  11. name
    Coutre SE
    type
    Author
  12. name
    Barr PM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wang XV
    type
    Author
  2. name
    Hanson CA
    type
    Author
  3. name
    Tschumper RC
    type
    Author
  4. name
    Lesnick CE
    type
    Author
  5. name
    Braggio E
    type
    Author
  6. name
    Paietta EM
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Barrientos JC
    type
    Author
  9. name
    Leis JF
    type
    Author
  10. name
    Zhang CC
    type
    Author
  11. name
    Coutre SE
    type
    Author
  12. name
    Barr PM
    type
    Author
bibliography ids
  1. nci-bib-dbca41418933bd1cd85a5f5a
book metadata
content sha256
87d9cfb44b6e8a6907aac40c8c186f22131a7c3e064cc1d43a4b7c4a709a7b7c
document type
citation
dois
  1. 10.1182/blood.2020010146
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34407545
immutable id
pubmed:34407545@87d9cfb44b6e8a6907aac40c8c186f22131a7c3e064cc1d43a4b7c4a709a7b7c
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
26
name
Blood
nlm unique id
7603509
pages
2810-2827
volume
138
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2021 Dec 30;138(26):2746-2747. doi: 10.1182/blood.2021013435.
    note
    Source null
    related pmid
    34967869
    relationship
    Comment in
outcomes validated
false
pmid
34407545
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
78904a593090853a002b21eb93dfcca2fb6cdc30155d246bbc4b7d3fc427e503
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Dec 30
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34407545/
title
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Preserved source evidence · Not medical advice